Rep. Lisa C. McClain Purchases Shares of Kenvue Inc. (NYSE:KVUE)

Representative Lisa C. McClain (R-Michigan) recently bought shares of Kenvue Inc. (NYSE:KVUE). In a filing disclosed on November 21st, the Representative disclosed that they had bought between $1,001 and $15,000 in Kenvue stock on October 30th. The trade occurred in the Representative’s “CHARLES SCHWAB 401K > SCHWAB 893” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

Kenvue Trading Up 1.1%

NYSE KVUE opened at $17.22 on Thursday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 0.98. Kenvue Inc. has a one year low of $14.02 and a one year high of $25.17. The firm has a market cap of $32.98 billion, a price-to-earnings ratio of 22.95 and a beta of 0.71. The firm has a 50 day simple moving average of $16.10 and a 200-day simple moving average of $19.65.

Kenvue (NYSE:KVUE) last released its earnings results on Monday, November 3rd. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. The firm had revenue of $3.76 billion for the quarter, compared to analyst estimates of $3.83 billion. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. The business’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.28 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Equities research analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, November 26th. Shareholders of record on Wednesday, November 12th were paid a dividend of $0.2075 per share. The ex-dividend date was Wednesday, November 12th. This represents a $0.83 dividend on an annualized basis and a yield of 4.8%. Kenvue’s dividend payout ratio is 110.67%.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. Royal Bank Of Canada reduced their price objective on Kenvue from $24.00 to $22.00 and set a “sector perform” rating for the company in a research note on Friday, August 8th. Zacks Research raised Kenvue to a “strong sell” rating in a report on Monday, August 11th. Weiss Ratings restated a “hold (c-)” rating on shares of Kenvue in a research note on Tuesday, October 14th. JPMorgan Chase & Co. decreased their price target on Kenvue from $24.00 to $21.00 and set an “overweight” rating for the company in a report on Friday, October 10th. Finally, Rothschild & Co Redburn raised shares of Kenvue from a “neutral” rating to a “buy” rating and dropped their price objective for the company from $22.50 to $22.00 in a research note on Friday, September 26th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $20.23.

Institutional Trading of Kenvue

Several hedge funds have recently modified their holdings of KVUE. CIBC Private Wealth Group LLC boosted its stake in shares of Kenvue by 20.1% in the third quarter. CIBC Private Wealth Group LLC now owns 6,388 shares of the company’s stock valued at $104,000 after buying an additional 1,068 shares in the last quarter. CIBC Bancorp USA Inc. purchased a new position in Kenvue in the third quarter worth $11,508,000. First Affirmative Financial Network acquired a new stake in Kenvue in the third quarter valued at $170,000. Danske Bank A S purchased a new stake in shares of Kenvue during the 3rd quarter worth $18,543,000. Finally, Caitong International Asset Management Co. Ltd boosted its position in shares of Kenvue by 25.4% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 16,954 shares of the company’s stock worth $275,000 after purchasing an additional 3,436 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.